This is mainly a scale-and-concentration risk, not a science-project risk. The products are real and margins are attractive, but Astera must prove
Scorpio breadth, reduce dependence on a handful of buyers, navigate outsourced supply constraints, and keep premium economics as open standards and larger rivals push on pricing.